{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:45:40Z","timestamp":1786992340170,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jfma.2025.06.039","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T23:00:53Z","timestamp":1751842853000},"page":"697-704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["High occurrence of antiphospholipid antibody-associated thromboembolism in systemic lupus erythematosus with significant pulmonary hypertension: A monocentric retrospective study in southern taiwan"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6392-2828","authenticated-orcid":false,"given":"Chia-Tse","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Shan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hui","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0312-0628","authenticated-orcid":false,"given":"Jun-Neng","family":"Roan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9881-7024","authenticated-orcid":false,"given":"Chrong-Reen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2025.06.039_bib1","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2025.06.039_bib2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1164\/rccm.202302-0327SO","article-title":"Pulmonary hypertension: a contemporary review","volume":"208","author":"Johnson","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jfma.2025.06.039_bib3","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2025.06.039_bib4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s11845-017-1727-4","article-title":"Prevalence of pulmonary hypertension in systemic lupus erythematosus: a meta-analysis","volume":"187","author":"Lv","year":"2018","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.jfma.2025.06.039_bib5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.autrev.2017.04.003","article-title":"Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: a systematic review and meta-analysis","volume":"16","author":"Zuily","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jfma.2025.06.039_bib6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11926-014-0478-8","article-title":"Pulmonary hypertension in antiphospholipid syndrome","volume":"17","author":"Zuily","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jfma.2025.06.039_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra0910203","article-title":"Chronic thromboembolic pulmonary hypertension","volume":"364","author":"Piazza","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.06.039_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2023.01.012","article-title":"Antiphospholipid antibodies in chronic thromboembolic pulmonary hypertension","volume":"111","author":"Zhu","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jfma.2025.06.039_bib9","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/jama.2012.12347","article-title":"Pulmonary hypertension","volume":"308","author":"Shah","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2025.06.039_bib10","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jfma.2025.06.039_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jfma.2025.06.039_bib12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra0907731","article-title":"Acute pulmonary embolism","volume":"363","author":"Agnelli","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.06.039_bib13","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/0961203311401458","article-title":"A retrospective study of pulmonary infarction in patients with systemic lupus erythematosus from southern Taiwan","volume":"20","author":"Weng","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.jfma.2025.06.039_bib14","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJM197706232962503","article-title":"Pulmonary embolism, pulmonary hemorrhage and pulmonary infarction","volume":"296","author":"Dalen","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.06.039_bib15","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/CIRCULATIONAHA.110.015008","article-title":"Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry","volume":"124","author":"Pepke-Zaba","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2025.06.039_bib16","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.jfma.2021.03.022","article-title":"Incidence of chronic thromboembolic pulmonary hypertension in Taiwan","volume":"120","author":"Liu","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2025.06.039_bib17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ejim.2013.04.009","article-title":"Echocardiographic estimation of pulmonary arterial systolic pressure in acute heart failure. Prognostic implications","volume":"24","author":"Merlos","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jfma.2025.06.039_bib18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.amjmed.2007.01.024","article-title":"Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution","volume":"120","author":"Moyssakis","year":"2007","journal-title":"Am J Med"},{"issue":"12 Suppl","key":"10.1016\/j.jfma.2025.06.039_bib19","doi-asserted-by":"crossref","first-page":"40S","DOI":"10.1016\/j.jacc.2004.02.032","article-title":"Diagnosis and differential assessment of pulmonary arterial hypertension","volume":"43","author":"Barst","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2025.06.039_bib20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/09612033221084230","article-title":"Pelvic deep venous thrombosis mimicking lower limb cellulitis in systemic lupus erythematosus-associated antiphospholipid syndrome","volume":"31","author":"Wang","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.jfma.2025.06.039_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.semarthrit.2016.02.002","article-title":"Rituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: a single-center experience","volume":"46","author":"Wang","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jfma.2025.06.039_bib22","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s10067-017-3971-4","article-title":"Lupus myocarditis receiving rituximab therapy-a monocentric retrospective study","volume":"37","author":"Wang","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jfma.2025.06.039_bib23","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0002-8703(92)90420-Z","article-title":"Cardiac manifestations of the antiphospholipid syndrome","volume":"124","author":"Kaplan","year":"1992","journal-title":"Am Heart J"},{"issue":"Suppl 3","key":"10.1016\/j.jfma.2025.06.039_bib24","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1513\/AnnalsATS.201512-802AS","article-title":"Medical therapy in chronic thromboembolic pulmonary hypertension","volume":"13","author":"Pepke-Zaba","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jfma.2025.06.039_bib25","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1253\/jcj.61.958","article-title":"Successful thromboendarterectomy for chronic pulmonary embolism in a patient with systemic lupus erythematosus and antiphospholipid syndrome","volume":"61","author":"Nakajima","year":"1997","journal-title":"Jpn Circ J"},{"key":"10.1016\/j.jfma.2025.06.039_bib26","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0003-4975(98)00910-2","article-title":"Operation for chronic pulmonary thromboembolism accompanied by thrombophilia in 8 patients","volume":"66","author":"Ando","year":"1998","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jfma.2025.06.039_bib27","first-page":"7","article-title":"Thromboendarterectomy as treatment in the antiphospholipid syndrome","volume":"8","author":"Peng","year":"2006","journal-title":"MedGenMed"},{"key":"10.1016\/j.jfma.2025.06.039_bib28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/RHU.0000000000000037","article-title":"Pulmonary hypertension in systemic lupus erythematosus: pulmonary thromboembolism is the leading cause","volume":"19","author":"Akdogan","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jfma.2025.06.039_bib29","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00296-011-2346-4","article-title":"Resolutive pulmonary endarterectomy in a non-compliant patient with systemic lupus erythematosus and antiphospholipid syndrome","volume":"33","author":"Kuzenko","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jfma.2025.06.039_bib30","article-title":"ANA Negative systemic lupus erythematosus leading to CTEPH, TTP-like thrombocytopenia, and skin ulcers","volume":"2016","author":"Changal","year":"2016","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.jfma.2025.06.039_bib31","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1177\/0961203318810427","article-title":"Pulmonary thromboendarterectomy is a curative resolution for chronic thromboembolic pulmonary hypertension associated with antiphospholipid syndrome: a retrospective cohort study","volume":"27","author":"Li","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.jfma.2025.06.039_bib32","article-title":"Thromboendarterectomy in a patient with systemic lupus and antiphospholipid syndrome, lessons learned from a complex disease interaction","volume":"2020","author":"Elmogy","year":"2020","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.jfma.2025.06.039_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/jaut.2000.0402","article-title":"Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus","volume":"15","author":"Alarcon-Segovia","year":"2000","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jfma.2025.06.039_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archinte.164.1.77","article-title":"High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus","volume":"164","author":"Ruiz-Irastorza","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jfma.2025.06.039_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/MD.0b013e31829cae47","article-title":"Prevalence of the antiphospholipid syndrome and its effect on survival in 679 Chinese patients with systemic lupus erythematosus- a cohort study","volume":"92","author":"Mok","year":"2013","journal-title":"Medicine"},{"key":"10.1016\/j.jfma.2025.06.039_bib36","first-page":"2850","article-title":"Frequency and predictors for chronic thromboembolic pulmonary hypertension after a first unprovoked pulmonary embolism: results from PADIS studies","volume":"vol. 20","year":"2022"},{"key":"10.1016\/j.jfma.2025.06.039_bib37","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0002-9343(58)90326-7","article-title":"Pulmonary embolism and infarction; a review of the physiologic consequences of pulmonary arterial obstruction","volume":"24","author":"Parker","year":"1958","journal-title":"Am J Med"},{"key":"10.1016\/j.jfma.2025.06.039_bib38","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/ard.47.10.869","article-title":"Pulmonary hemorrhage, pulmonary infarction, and the lupus anticoagulant","volume":"47","author":"Howe","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfma.2025.06.039_bib39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.thromres.2021.03.022","article-title":"Pulmonary infarction in acute pulmonary embolism","volume":"202","author":"Kaptein","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jfma.2025.06.039_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0061-2017","article-title":"Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signaling in lung disease","volume":"26","author":"Kanaan","year":"2017","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jfma.2025.06.039_bib41","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2025.06.039_bib42","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.jacc.2018.04.009","article-title":"Chronic thromboembolic pulmonary hypertension: evolving therapeutic approaches for operable and inoperable disease","volume":"71","author":"Mahmud","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2025.06.039_bib43","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/jth.14705","article-title":"Direct oral anticoagulants in thrombotic antiphospholipid syndrome associated with chronic thromboembolic pulmonary hypertension","volume":"18","author":"Porres-Aguilar","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jfma.2025.06.039_bib44","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1365-2125.2005.02361.x","article-title":"Is INR between 20 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?","volume":"59","author":"You","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jfma.2025.06.039_bib45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10928-009-9138-4","article-title":"Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin","volume":"37","author":"Yuen","year":"2010","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625003304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625003304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:25:21Z","timestamp":1781825121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625003304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0929664625003304"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.06.039","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High occurrence of antiphospholipid antibody-associated thromboembolism in systemic lupus erythematosus with significant pulmonary hypertension: A monocentric retrospective study in southern taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.06.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}